ReviewBMC medical genomics2026
First published report of the FLCN c.1222 C > T (p.Gln408Ter) variant in a Chinese family with Birt-Hogg-Dubé syndrome and literature review.
Review in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBirt–Hogg–Dubé syndrome (BHDS) is a rare inherited disorder defined by skin lesions, pulmonary cysts, spontaneous pneumothorax, and renal neoplasia. Mutations in the FLCN gene are known causes, and identifying specific variants in different populations is essential for elucidating genotype-phenotype correlations.
methodsWe investigated a Chinese family with suspected BHDS. The proband was admitted to the Affiliated Cangnan Hospital of Wenzhou Medical University in October 2023. Comprehensive clinical evaluations and imaging studies were performed. Peripheral blood samples were collected from the proband and available family members after obtaining informed consent. Whole-exome sequencing (WES) was conducted to identify potential variants in the FLCN gene. Candidate variants were subsequently validated by Sanger sequencing and analyzed for co-segregation within the family. Pathogenicity was assessed in accordance with the American College of Medical Genetics and Genomics (ACMG) guidelines. To illustrate the structural impact of the variant, a three-dimensional model of the folliculin protein was generated using SWISS-MODEL and visualized with PyMOL.
resultsThe proband exhibited bilateral pulmonary cysts, a small left-sided pneumothorax, a left renal mass, and possible cutaneous manifestations. Family evaluation identified pulmonary cysts in multiple children, with pneumothorax in some and a history of lobectomy in two. Genetic testing revealed a heterozygous FLCN nonsense variant, NM_144997.7:c.1222 C > T (p.Gln408Ter), in the proband and one son, while her husband and asymptomatic daughter were noncarriers. This variant meets ACMG criteria for pathogenicity. Structural modeling demonstrated that the premature stop codon truncates folliculin at residue 408, eliminating most of the C-terminal domain and severely compromising protein integrity. Although this variant is listed in ClinVar (RCV001953597) as pathogenic, detailed phenotypic documentation has been limited, and it has not been previously described in Chinese BHDS patients.
conclusionsWe describe, to our knowledge, the first report of the FLCN NM_144997.7:c.1222 C > T (p.Gln408Ter) variant in a Chinese BHDS family and characterize its associated clinical phenotype. These findings extend the known FLCN variant spectrum, enhance population-specific genotype–phenotype understanding, and offer meaningful evidence for clinical diagnosis and genetic counseling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.